
PathGroup Acquires SkinDx, Expanding Dermatopathology Services

Combination provides enhanced services for SkinDx clients, supports continued excellence in dermatopathology

NASHVILLE, June 16, 2021 — PathGroup, one of the largest providers of anatomic pathology, digital pathology, clinical and molecular laboratory services in the United States, announced the acquisition of SkinDx, a leading dermatopathology laboratory in the Southeastern U.S., based in Birmingham, Alabama. This acquisition expands PathGroup's presence in the dermatopathology space, while also providing state-of-the-art molecular pathology and clinical pathology services for current SkinDx clients.

The addition of SkinDx extends PathGroup's significant commitment and strategic initiative to provide clinical services to dermatologists, and builds on the company's previous acquisition of Atlanta Dermatopathology. By combining forces, PathGroup and SkinDx will provide comprehensive dermatopathology services for physicians and patients in the Southeast, Midwest and Mid-Atlantic regions. PathGroup now has a team of more than 185 pathologists covering every subspecialty, expanding the company's commitment to superior pathology services.

"SkinDx and PathGroup are both dedicated to providing superior service levels and the highest quality dermatopathology services to our clients and patients," said Dr. Alan Long, SkinDx's Founder and Chief Executive Officer. "PathGroup, with their culture of physician leadership and history of diagnostic excellence, is a perfect match for SkinDx's culture and values."

"We are proud of our combined company of more than 2,500 employees working with hospitals, physicians and patients across the United States, as we expand our dermatopathology laboratory services with the team at SkinDx," said Ben W. Davis, M.D., President and Chief Executive Officer of PathGroup. "We continue to look for opportunities to better serve physicians and patients across our 25-state region and look forward to introducing the SkinDx physician team to our clients."

About PathGroup

Founded in 1965, PathGroup is a premier provider of anatomic, clinical, molecular, and digital pathology services in the United States. Privately held and physician-centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers, and most importantly, patients. One Lab; Total Service. PathGroup is owned by Pritzker Private Capital along with management. For more information, visit pathgroup.com.

About Pritzker Private Capital

Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products, services, and health-care sectors. The firm's differentiated, long-duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur- and family-owned companies. Pritzker Private Capital is a signatory to the United Nations Principles for Responsible Investment (PRI). For more information, visit PPCPartners.com.

Contacts

PathGroup Corporate:
Richard A. Halstead
EVP, Chief Commercial Officer
615-234-3915
rhalstead@pathgroup.com